{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:33:29Z","timestamp":1790552009192,"version":"4.1.0"},"reference-count":156,"publisher":"Elsevier","isbn-type":[{"value":"9780128188552","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.pmbts.2019.06.005","type":"book-chapter","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T19:53:29Z","timestamp":1570478009000},"page":"25-75","source":"Crossref","is-referenced-by-count":122,"title":["Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings"],"prefix":"10.1016","author":[{"given":"Sonja","family":"Elsaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kloiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Le Foll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/bs.pmbts.2019.06.005_bb0010","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF02862859","article-title":"An archaeological and historical account of cannabis in China","volume":"28","author":"Li","year":"1974","journal-title":"Econ Bot"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/02791072.1978.10471863","article-title":"Hallucinogenic plants in Chinese herbals","volume":"10","author":"Li","year":"1978","journal-title":"J Psychodelic Drugs"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02791072.1981.10471447","article-title":"The religious and medicinal uses of Cannabis in China, India and Tibet","volume":"13","author":"Touwn","year":"1981","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.06.005_bb0025","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1590\/S1516-44462006000200015","article-title":"History of cannabis as a medicine: a review","volume":"28","author":"Zuardi","year":"2006","journal-title":"Rev Bras Psiquiatr"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0030","series-title":"Cannabis and Cannabinoids","first-page":"37","article-title":"History of cannabis in Western medicine","author":"Fankhauser","year":"2002"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0035","series-title":"Cannabis and Culture","first-page":"293","article-title":"Social and medical aspects of the use of cannabis in Brazil","author":"Pinho","year":"1975"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0040","first-page":"34","article-title":"Marijuana in medicine: past, present and future","volume":"110","author":"Mikuriya","year":"1969","journal-title":"Calif Med"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0045","series-title":"Cannabis in Medical Practice","first-page":"35","article-title":"History of therapeutic cannabis","author":"Aldrich","year":"1997"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0050","series-title":"History of Cannabis","first-page":"1","article-title":"Marihuana: the forbidden medicine","author":"Grinspoon","year":"1993"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0055","series-title":"Psychopharmacology: A Generation of Progress","first-page":"1565","article-title":"Cannabis: a review of progress","author":"Harris","year":"1978"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.06.005_bb0060","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archpsyc.1984.01790130096013","article-title":"Marihuana users in young adulthood","volume":"41","author":"Kandel","year":"1984","journal-title":"Arch Gen Psychiatry"},{"issue":"pt. B","key":"10.1016\/bs.pmbts.2019.06.005_bb0065","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.yebeh.2016.11.021","article-title":"The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law","volume":"70","author":"Mead","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0070","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cropro.2018.11.003","article-title":"Cannabis as conundrum","volume":"117","author":"Sandler","year":"2019","journal-title":"Crop Prot"},{"issue":"8","key":"10.1016\/bs.pmbts.2019.06.005_bb0075","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/cbdv.200790144","article-title":"History of cannabis and its preparations in saga, science, and sobriquet","volume":"4","author":"Russo","year":"2007","journal-title":"Chem Biodivers"},{"issue":"8","key":"10.1016\/bs.pmbts.2019.06.005_bb0080","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","article-title":"The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis","volume":"29","author":"D'Souza","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"S1","key":"10.1016\/bs.pmbts.2019.06.005_bb0085","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1002\/j.1552-4604.2002.tb05998.x","article-title":"Cannabidiol: an overview of some pharmacological aspects","volume":"42","author":"Mechoulam","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2017.02.041","article-title":"Cannabidiol: state of the art and new challenges for therapeutic applications","volume":"175","author":"Pisanti","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.06.005_bb0095","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/157488611798280924","article-title":"Safety and side effects of cannabidiol, a Cannabis sativa constituent","volume":"6","author":"Bergamaschi","year":"2011","journal-title":"Curr Drug Saf"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0100","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/3-540-26573-2_23","article-title":"Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol","volume":"168","author":"Huestis","year":"2005","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0105","series-title":"Metabolism and Pharmacokinetics of Cannabinoids","author":"Hawksworth","year":"2004"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0110","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","article-title":"A systematic review on the pharmacokinetics of cannabidiol in humans","volume":"9","author":"Millar","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1300\/J175v03n04_01","volume":"3","author":"Guy","year":"2004","journal-title":"J Cannabis Ther"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.06.005_bb0120","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.06.005_bb0125","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/cpt.441","article-title":"The utility of cannabidiol in the treatment of refractory epilepsy","volume":"101","author":"Reddy","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0130","series-title":"The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects","first-page":"219","article-title":"Single dose kinetics of cannabidiol in man","author":"Ohlsson","year":"1984"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.06.005_bb0135","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0091-3057(91)90358-9","article-title":"Comparative metabolism of cannabidiol in dog, rat and man","volume":"40","author":"Harvey","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0140","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1089\/can.2015.0012","article-title":"Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy","volume":"1","author":"Ujv\u00e1ry","year":"2016","journal-title":"Cannabis Cannabinoid Res"},{"issue":"5\u20136","key":"10.1016\/bs.pmbts.2019.06.005_bb0145","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lfs.2011.05.018","article-title":"Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes","volume":"89","author":"Jiang","year":"2011","journal-title":"Life Sci"},{"issue":"20","key":"10.1016\/bs.pmbts.2019.06.005_bb0150","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.06.005_bb0155","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","article-title":"Molecular targets of cannabidiol in neurological disorders","volume":"12","author":"Ibeas Bih","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0160","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fphar.2017.00269","article-title":"Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders","volume":"8","author":"Campos","year":"2017","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.06.005_bb0165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0170","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0175","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/npp.2015.367","article-title":"Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis","volume":"41","author":"Haney","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0180","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/npp.2017.209","article-title":"Clinical and preclinical evidence for functional interactions of cannabidiol and delta(9)-tetrahydrocannabinol","volume":"43","author":"Boggs","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0185","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects ofcannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/bs.pmbts.2019.06.005_bb0190","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1A receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem Res"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0195","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/bs.pmbts.2019.06.005_bb0200","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.pnpbp.2009.08.017","article-title":"Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids","volume":"33","author":"Campos","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0205","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/1074248414532013","article-title":"The effect of cannabidiol on ischemia\/reperfusion-induced ventricular arrhythmias: the role ofadenosine A1 receptors","volume":"20","author":"Gonca","year":"2015","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0210","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00210-006-0033-x","article-title":"Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors","volume":"372","author":"Kathmann","year":"2006","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0215","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/can.2018.0022","article-title":"Emerging evidence for cannabis' role in opioid use disorder","volume":"3","author":"Wiese","year":"2018","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0220","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1152\/physrev.00042.2003","article-title":"Molecular structure and function of the glycine receptor chloride channel","volume":"84","author":"Lynch","year":"2004","journal-title":"Physiol Rev"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.06.005_bb0225","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3390\/ph5050529","article-title":"Cannabidiol in humans-the quest for therapeutic targets","volume":"5","author":"Zhornitsky","year":"2012","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"7","key":"10.1016\/bs.pmbts.2019.06.005_bb0230","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ptr.5095","article-title":"Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARgamma involvement","volume":"28","author":"Scuderi","year":"2014","journal-title":"Phytother Res"},{"issue":"2\u20133","key":"10.1016\/bs.pmbts.2019.06.005_bb0235","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/FBP.0000000000000247","article-title":"The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease","volume":"28","author":"Karl","year":"2017","journal-title":"Behav Pharmacol"},{"issue":"41","key":"10.1016\/bs.pmbts.2019.06.005_bb0240","doi-asserted-by":"crossref","first-page":"12957","DOI":"10.1523\/JNEUROSCI.1064-09.2009","article-title":"Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin\/NFAT signaling","volume":"29","author":"Abdul","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0245","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejphar.2013.10.011","article-title":"Effects of cannabidiol on the function of \u03b17-nicotinic acetylcholine receptors","volume":"720","author":"Mahgoub","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0250","doi-asserted-by":"crossref","first-page":"16124","DOI":"10.1074\/jbc.M707104200","article-title":"Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol","volume":"283","author":"Ross","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0255","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.neulet.2014.03.013","article-title":"Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se","volume":"566","author":"Hill","year":"2014","journal-title":"Neurosci Lett"},{"issue":"10","key":"10.1016\/bs.pmbts.2019.06.005_bb0260","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose","volume":"6","author":"Seeman","year":"2016","journal-title":"Transl Psychiatry"},{"issue":"11","key":"10.1016\/bs.pmbts.2019.06.005_bb0265","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1021\/cn5000524","article-title":"Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability","volume":"5","author":"Iannotti","year":"2014","journal-title":"ACS Chem Nerosci"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.06.005_bb0270","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1124\/jpet.109.159145","article-title":"Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo","volume":"332","author":"Jones","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/bs.pmbts.2019.06.005_bb0275","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1111\/bph.14202","article-title":"Cannabidiol exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal lobe epilepsy model","volume":"175","author":"Khan","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0280","first-page":"26","article-title":"Cannabidiol\u2014antiepileptic drug comparisons and interactions in experimentally induced seizures in rats","volume":"201","author":"Consroe","year":"1977","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.06.005_bb0285","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0014-2999(82)90264-3","article-title":"Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice","volume":"83","author":"Consroe","year":"1982","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.06.005_bb0290","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.seizure.2012.03.001","article-title":"Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures","volume":"21","author":"Jones","year":"2012","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yebeh.2013.03.009","article-title":"The role of potassium BK channels in anticonvulsant effect of cannabidiol in pentylenetetrazole and maximal electroshock models of seizure in mice","volume":"28","author":"Shirazi-zand","year":"2013","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.06.005_bb0300","first-page":"8820","article-title":"High dosage of cannabidiol (CBD) alleviates pentylenetetrazole-induced epilepsy in rats by exerting an anticonvulsive effect","volume":"8","author":"Mao","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0305","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1203\/PDR.0b013e318186e5dd","article-title":"Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets","volume":"64","author":"Alvarez","year":"2008","journal-title":"Pediatr Res"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0310","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13041-018-0395-2","article-title":"Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor","volume":"11","author":"Rodriguez-Munoz","year":"2018","journal-title":"Mol Brain"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.06.005_bb0315","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF00450585","article-title":"Toward drugs derived from cannabis","volume":"65","author":"Mechoulam","year":"1978","journal-title":"Naturwissenschaften"},{"issue":"S1","key":"10.1016\/bs.pmbts.2019.06.005_bb0320","doi-asserted-by":"crossref","first-page":"417S","DOI":"10.1002\/j.1552-4604.1981.tb02622.x","article-title":"Hypnotic and antiepileptic effects of cannabidiol","volume":"21","author":"Carlini","year":"1981","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0325","first-page":"14","article-title":"Anticonvulsant effect of cannabidiol","volume":"69","author":"Ames","year":"1986","journal-title":"S Afr Med J"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.06.005_bb0330","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/bs.pmbts.2019.06.005_bb0335","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1111\/epi.13815","article-title":"Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol","volume":"58","author":"Rosenberg","year":"2017","journal-title":"Epilepsia"},{"issue":"21","key":"10.1016\/bs.pmbts.2019.06.005_bb0340","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0345","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/0883073816669450","article-title":"Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases","volume":"32","author":"Gofshteyn","year":"2017","journal-title":"J Child Neurol"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.06.005_bb0350","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in Huntington's disease. Special Issue: Pharmacological, chemical, biochemical and behavioral research on cannabis and the cannabinoids","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"issue":"8","key":"10.1016\/bs.pmbts.2019.06.005_bb0355","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/0269881108096519","article-title":"Cannabidiol for the treatment of psychosis in Parkinsons disease","volume":"23","author":"Zuardi","year":"2009","journal-title":"J Psychopharmacol"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.06.005_bb0360","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/jcpt.12179","article-title":"Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series","volume":"39","author":"Chagas","year":"2014","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"10.1016\/bs.pmbts.2019.06.005_bb0365","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881114550355","article-title":"Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial","volume":"28","author":"Chagas","year":"2014","journal-title":"J Psychopharmacol"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.06.005_bb0370","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s11064-018-2513-z","article-title":"Cannabidiol reverses deficits in hippocampal LTP in a model of Alzheimer's disease","volume":"44","author":"Hughes","year":"2019","journal-title":"Neurochem Res"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.06.005_bb0375","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00109-005-0025-1","article-title":"The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt\/beta-catenin pathway rescue in PC12 cells","volume":"84","author":"Esposito","year":"2006","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0380","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1471-4159.2003.02327.x","article-title":"Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells","volume":"89","author":"Iuvone","year":"2004","journal-title":"J Neurochem"},{"issue":"1 suppl 1","key":"10.1016\/bs.pmbts.2019.06.005_bb0385","article-title":"Cannabidiol, a non-psychoactive marijuana component, exhibits antioxidant and neuroprotective effects in neuronal Alzheimer's cell model SH-5Y","volume":"32","author":"Briggs","year":"2018","journal-title":"FASEB J"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.06.005_bb0390","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1124\/mol.111.071290","article-title":"Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease","volume":"79","author":"Martin-Moreno","year":"2011","journal-title":"Mol Pharmacol"},{"issue":"8","key":"10.1016\/bs.pmbts.2019.06.005_bb0395","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/sj.bjp.0707337","article-title":"Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression","volume":"151","author":"Esposito","year":"2007","journal-title":"Br J Pharmacol"},{"issue":"15","key":"10.1016\/bs.pmbts.2019.06.005_bb0400","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1007\/s00213-014-3478-5","article-title":"Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe\/PS1E9 mice","volume":"231","author":"Cheng","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.06.005_bb0405","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3233\/JAD-140921","article-title":"Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice","volume":"42","author":"Cheng","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.06.005_bb0410","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/mol.115.101980","article-title":"Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington diseases","volume":"89","author":"Laprairie","year":"2016","journal-title":"Mol Pharmacol"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.06.005_bb0415","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1460-9568.2007.05717.x","article-title":"Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors","volume":"26","author":"Sagredo","year":"2007","journal-title":"Eur J Neurosci"},{"issue":"9","key":"10.1016\/bs.pmbts.2019.06.005_bb0420","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/jnr.22682","article-title":"Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease","volume":"89","author":"Sagredo","year":"2011","journal-title":"J Neurosci Res"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.06.005_bb0425","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/cn200114w","article-title":"Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors","volume":"3","author":"Valdeolivas","year":"2012","journal-title":"ACS Chem Nerosci"},{"issue":"1\u20132","key":"10.1016\/bs.pmbts.2019.06.005_bb0430","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","article-title":"Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease","volume":"19","author":"Lastres-Becker","year":"2005","journal-title":"Neurobiol Dis"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0435","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","article-title":"Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties","volume":"1134","author":"Garc\u00eda-Arencibia","year":"2007","journal-title":"Brain Res"},{"issue":"suppl 2","key":"10.1016\/bs.pmbts.2019.06.005_bb0440","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.1016\/S1353-8020(11)70883-5","article-title":"Phytocannabinoids tetrahydrocannabinol and cannabidiol ACT against rotenone induced damages in murine cell cultures","volume":"18","author":"Moldzio","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"issue":"8\u20139","key":"10.1016\/bs.pmbts.2019.06.005_bb0445","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.phymed.2012.04.002","article-title":"Effects of cannabinoids DELTA(9)-tetrahydrocannabinol, DELTA(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures","volume":"19","author":"Moldzio","year":"2012","journal-title":"Phytomedicine"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0450","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.neuropharm.2017.08.017","article-title":"GPR55: a therapeutic target for Parkinson's disease?","volume":"125","author":"Celorrio","year":"2017","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0455","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12035-013-8514-7","article-title":"Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection","volume":"49","author":"da Silva","year":"2014","journal-title":"Mol Neurobiol"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0460","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pnpbp.2013.06.005","article-title":"Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice","volume":"46","author":"Gomes","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.06.005_bb0465","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejphar.2005.02.040","article-title":"Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice","volume":"512","author":"Moreira","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10.1016\/bs.pmbts.2019.06.005_bb0470","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1017\/S1461145709990605","article-title":"A behavioural comparison of acute and chronic \u03949-tetrahydrocannabinol and cannabidiol in C57BL\/6JArc mice","volume":"13","author":"Long","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"issue":"18","key":"10.1016\/bs.pmbts.2019.06.005_bb0475","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1523\/JNEUROSCI.3387-15.2016","article-title":"Cannabidiol counteracts amphetamine-induced neuronal and behavioral sensitization of the mesolimbic dopamine pathway through a novel mTOR\/p70S6 kinase signaling pathway","volume":"36","author":"Renard","year":"2016","journal-title":"J Neurosci"},{"issue":"16","key":"10.1016\/bs.pmbts.2019.06.005_bb0480","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1007\/s00213-015-3945-7","article-title":"Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine","volume":"232","author":"Pedrazzi","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.06.005_bb0485","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF02244189","article-title":"Effects of cannabidiol in animal models predictive of antipsychotic activity","volume":"104","author":"Zuardi","year":"1991","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0490","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbr.2016.04.042","article-title":"Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice","volume":"309","author":"Sonego","year":"2016","journal-title":"Behav Brain Res"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0495","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/sj.npp.1300838","article-title":"Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice","volume":"31","author":"Long","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.06.005_bb0500","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbr.2011.03.053","article-title":"Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia","volume":"222","author":"Gururajan","year":"2011","journal-title":"Behav Brain Res"},{"issue":"8 Specl pt. 3","key":"10.1016\/bs.pmbts.2019.06.005_bb0505","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/FBP.0000000000000178","article-title":"MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol","volume":"26","author":"Deiana","year":"2015","journal-title":"Behav Pharmacol"},{"issue":"10","key":"10.1016\/bs.pmbts.2019.06.005_bb0510","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1177\/0269881112441865","article-title":"Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats","volume":"26","author":"Gururajan","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.06.005_bb0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034129","article-title":"Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice","volume":"7","author":"Long","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/bs.pmbts.2019.06.005_bb0520","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/npp.2017.40","article-title":"Improved social interaction, recognition and working memory with cannabidiol treatment in a prenatal infection (poly I:C) rat model","volume":"42","author":"Osborne","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"10.1016\/bs.pmbts.2019.06.005_bb0525","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.schres.2016.02.004","article-title":"Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia","volume":"172","author":"Peres","year":"2016","journal-title":"Schizophr Res"},{"issue":"10","key":"10.1016\/bs.pmbts.2019.06.005_bb0530","first-page":"485","article-title":"Antipsychotic effect of cannabidiol","volume":"56","author":"Zuardi","year":"1995","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.06.005_bb0535","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/0269881106060967","article-title":"Cannabidiol monotherapy for treatment-resistant schizophrenia","volume":"20","author":"Zuardi","year":"2006","journal-title":"J Psychopharmacol"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0540","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1590\/S1516-44462010000100011","article-title":"Performance of schizophrenic patients in the stroop color word test and electrodermal responsiveness after acute administration of cannabidiol (CBD)","volume":"32","author":"Hallak","year":"2010","journal-title":"Rev Bras Psiquiatr"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0545","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl Psychiatry"},{"issue":"7","key":"10.1016\/bs.pmbts.2019.06.005_bb0550","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","article-title":"The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial","volume":"235","author":"Boggs","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.06.005_bb0555","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0560","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report","volume":"25","author":"Crippa","year":"2011","journal-title":"J Psychopharmacol"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.06.005_bb0565","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0570","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7812\/TPP\/18-041","article-title":"Cannabidiol in anxiety and sleep: a large case series","volume":"23","author":"Shannon","year":"2019","journal-title":"Perm J"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0575","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/0269881108096521","article-title":"Cannabidiol was ineffective for manic episode of bipolar affective disorder","volume":"24","author":"Zuardi","year":"2010","journal-title":"J Psychopharmacol"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0580","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","article-title":"Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers","volume":"172","author":"Babalonis","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0585","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/can.2017.0043","article-title":"Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular Cannabis users: a pragmatic open-label clinical trial","volume":"3","author":"Solowij","year":"2018","journal-title":"Cannabis Cannabinoid Res"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.06.005_bb0590","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jcpt.12018","article-title":"Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report","volume":"38","author":"Crippa","year":"2013","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.06.005_bb0595","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/ADM.0000000000000118","article-title":"Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans","volume":"9","author":"Manini","year":"2015","journal-title":"J Addict Med"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.06.005_bb0600","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s13311-015-0373-7","article-title":"Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage","volume":"12","author":"Hurd","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0605","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00431988","article-title":"Interaction of cannabidiol and alcohol in humans","volume":"66","author":"Consroe","year":"1979","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"10.1016\/bs.pmbts.2019.06.005_bb0610","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","article-title":"Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings","volume":"38","author":"Morgan","year":"2013","journal-title":"Addict Behav"},{"issue":"9","key":"10.1016\/bs.pmbts.2019.06.005_bb0615","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/add.14243","article-title":"Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal","volume":"113","author":"Hindocha","year":"2018","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0620","doi-asserted-by":"crossref","first-page":"7568","DOI":"10.1038\/s41598-018-25846-2","article-title":"The effects of cannabidiol on impulsivity and memory during abstinence in cigarette dependent smokers","volume":"8","author":"Hindocha","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.06.005_bb0625","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF02244012","article-title":"Antianxiety effect of cannabidiol in the elevated plus-maze","volume":"100","author":"Guimar\u00e3es","year":"1990","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"10.1016\/bs.pmbts.2019.06.005_bb0630","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.pnpbp.2006.06.004","article-title":"Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test","volume":"30","author":"Moreira","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0635","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00213-012-2878-7","article-title":"Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats","volume":"226","author":"Campos","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0640","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0269881110389095","article-title":"Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT1A receptors","volume":"26","author":"Gomes","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"12","key":"10.1016\/bs.pmbts.2019.06.005_bb0645","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.euroneuro.2008.07.001","article-title":"Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats","volume":"18","author":"Bitencourt","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.06.005_bb0650","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bbr.2010.05.004","article-title":"Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors","volume":"213","author":"Soares","year":"2010","journal-title":"Behav Brain Res"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.06.005_bb0655","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.pbb.2011.06.027","article-title":"Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress","volume":"99","author":"Granjeiro","year":"2011","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0660","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1476-5381.2008.00046.x","article-title":"5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats","volume":"156","author":"Resstel","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.06.005_bb0665","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.euroneuro.2013.10.012","article-title":"Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience","volume":"24","author":"Foga\u00e7a","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0670","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/npp.2012.63","article-title":"On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment","volume":"37","author":"Stern","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/bs.pmbts.2019.06.005_bb0675","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1177\/0269881113493363","article-title":"The role of 5-HT1A receptors in the anti-aversive effects of cannabidiol on panic attack-like behaviors evoked in the presence of the wild snake Epicrates cenchria crassus (Reptilia, Boidae)","volume":"27","author":"Twardowschy","year":"2013","journal-title":"J Psychopharmacol"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0680","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejphar.2015.03.051","volume":"758","author":"da Silva","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.06.005_bb0685","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/fcp.12051","article-title":"Cannabidiol reverses the mCPP-induced increase in marble-burying behavior","volume":"28","author":"Nardo","year":"2014","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0690","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","article-title":"Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: role of 5-HT1A receptors","volume":"103","author":"Linge","year":"2016","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.06.005_bb0695","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000443890","article-title":"Prohedonic effect of cannabidiol in a rat model of depression","volume":"73","author":"Shoval","year":"2016","journal-title":"Neuropsychobiology"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.06.005_bb0700","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/0269881109106925","article-title":"Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania","volume":"25","author":"Valvassori","year":"2009","journal-title":"J Psychopharmacol"},{"issue":"47","key":"10.1016\/bs.pmbts.2019.06.005_bb0705","doi-asserted-by":"crossref","first-page":"14764","DOI":"10.1523\/JNEUROSCI.4291-09.2009","article-title":"Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances","volume":"29","author":"Ren","year":"2009","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.06.005_bb0710","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-0043-117838","article-title":"Effects of cannabidiol on morphine conditioned place preference in mice","volume":"84","author":"Markos","year":"2018","journal-title":"Planta Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0715","first-page":"185","article-title":"Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats","volume":"12","author":"Hine","year":"1975","journal-title":"Res Commun Chem Pathol Pharmacol"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.06.005_bb0720","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00426828","article-title":"Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice","volume":"49","author":"Bhargava","year":"1976","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0725","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0091-3057(85)90122-4","article-title":"The quasi-morphine withdrawal syndrome: effect of cannabinol, cannabidiol and tetrahydrocannabinol","volume":"23","author":"Chesher","year":"1985","journal-title":"Pharmacol Biochem Behav"},{"issue":"1\u20133","key":"10.1016\/bs.pmbts.2019.06.005_bb0730","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drugalcdep.2007.11.017","article-title":"Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of \u0394\u02c69-tetrahydrocannabinol","volume":"94","author":"Vann","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"13","key":"10.1016\/bs.pmbts.2019.06.005_bb0735","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1111\/bph.14226","article-title":"Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal","volume":"175","author":"Navarrete","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0740","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pbb.2013.08.013","article-title":"Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder","volume":"111","author":"Liput","year":"2013","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.06.005_bb0745","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1124\/jpet.105.085779","article-title":"Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity","volume":"314","author":"Hamelink","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0750","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/adb.12495","article-title":"Cannabidiol reduces ethanol consumption, motivation and relapse in mice","volume":"23","author":"Viudez-Martinez","year":"2018","journal-title":"Addict Biol"},{"issue":"10","key":"10.1016\/bs.pmbts.2019.06.005_bb0755","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/s41386-018-0050-8","article-title":"Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle","volume":"43","author":"Gonzalez-Cuevas","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.pmbts.2019.06.005_bb0760","first-page":"1","article-title":"Effects of cannabidiol on alcohol-related outcomes: a review of preclinical and human research","author":"Nona","year":"2019","journal-title":"Exp Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.06.005_bb0765","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/acer.13964","article-title":"Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: a systematic review","volume":"43","author":"Turna","year":"2019","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.06.005_bb0770","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1369-1600.2012.00483.x","article-title":"Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus","volume":"18","author":"Katsidoni","year":"2013","journal-title":"Addict Biol"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.06.005_bb0775","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/0269881116667706","article-title":"Effects of an acute cannabidiol treatment on cocaine self-administration and cue-induced cocaine seeking in male rats","volume":"31","author":"Mahmud","year":"2017","journal-title":"J Psychopharmacol"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.06.005_bb0780","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00213-004-1825-7","article-title":"Effect of low doses of \u03949-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats","volume":"175","author":"Parker","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"10.1016\/bs.pmbts.2019.06.005_bb0785","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1177\/0269881118799954","article-title":"Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats","volume":"32","author":"Hay","year":"2018","journal-title":"J Psychopharmacol"}],"container-title":["Progress in Molecular Biology and Translational Science","Molecular Basis of Neuropsychiatric Disorders: from Bench to Bedside"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187711731930095X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187711731930095X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T04:45:05Z","timestamp":1664599505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187711731930095X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128188552"],"references-count":156,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2019.06.005","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}